6953-61-3
                        6953-61-3 结构式
                    基本信息
Naphthohydroxamicacid
a-Naphthohydroxamic acid
1-NAPHTHOHYDROXAMIC ACID
alpha-naphthohydroxamicacid
1-NAPHTHOHYDROXAMIC ACID 98+%
HDAC Inhibitor XIX, Compound 2
1-Naphthalenecarbohydroximic acid
n-hydroxy-1-naphthalenecarboxamid
N-Hydroxy-1-naphthalenecarboxamide
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 | 
| 2025/05/22 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid  | 6953-61-3 | 1 mg | 175元 | 
| 2025/05/22 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid  | 6953-61-3 | 5mg | 404元 | 
| 2025/05/22 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid  | 6953-61-3 | 10mg | 665元 | 
常见问题列表
| 
   HDAC8 14 μM (IC 50 )  | 
 
   HDAC1 >100 μM (IC 50 )  | 
 
   HDAC6 >100 μM (IC 50 )  | 
  1-Naphthohydroxamic acid (compound 2; 20-40 µM; 0-144  hours; BE(2)-C, SK-N-BE(2) and SH-SY5Y cells) treatment reduces cell numbers in a concentration-dependent manner.
  
  1-Naphthohydroxamic acid (compound 2) at concentrations in the range of its in vitro IC
  
   50
  
  against HDAC8 results in reduced cell density and outgrowth of neurite-like structures that stained positive for neurofilament.1-Naphthohydroxamic acid reduces the formation of clones in soft-agar concentration dependently.
  
  When either cell type (HeLa and HEK293 cells) is treated with 1-Naphthohydroxamic acid (compound 2; 0.8 µM, 4 µM, 20 µM or 100 µM), only tubulin becomes hyperacetylated.
 
Cell Proliferation Assay
| Cell Line: | BE(2)-C, SK-N-BE(2) and SH-SY5Y cells | 
| Concentration: | 20 µM, 40 µM | 
| Incubation Time: | 0 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 144 hours | 
| Result: | Reduced cell numbers in a concentration-dependent manner. | 
  Dose-limiting toxicities (DLTs) of 1-Naphthohydroxamic acid (compound 2; 0-40 mg/kg; intraperitoneal injection; daily; for 10 day; NMRI
  
   Foxn1
  
  nude mice) include weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. 1-Naphthohydroxamic acid has the maximum tolerable doses at 50 mg/kg per day. At these concentrations, neither body weight nor blood parameters are critically changed.
  
  Pharmacokinetic studies after intraperitoneal administration of the inhibitors identified the half-life of 1-Naphthohydroxamic acid to be ~15 min, with a plasma peak concentration of ~30 μM.
 
| Animal Model: | NMRI Foxn1 nude mice | 
| Dosage: | 0 mg/kg, 50 mg/kg, 100mg/kg, 200 mg/kg, 300 mg/kg 400 mg/kg | 
| Administration: | Intraperitoneal injection; daily; for 10 days | 
| Result: | Dose-limiting toxicities (DLTs) included weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. | 
